← Leaderboards
Azucena (susy) Ramos
Harvard Medical School
$151,080
Attributed
$151,080
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $51K · FY2018–21$100K$75K$50K$25K$0
'18
'19
'20
'21
Funding mix
By agency
NIH$151,080 · 1
By mechanism
F31$151,080 · 1
Top collaborators
No co-investigators on record.
Most similar at Harvard Medical School
Same institution · by research overlap
- Norbert Perrimon$95,273,017
- Michaela Ulrike Gack$22,395,027
- Scott Garwood Kennedy$14,893,850
- Eric F. Joyce$5,371,149
- Angela Elizabeth Zou$148,389
Others in their field
Other Emerging Leaders on “Acute Myelocytic Leukemia”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Leonard Freedman · Leidos Biomedical Research, Inc.$12,430,568
- Crystal Mackall · Children'S Hosp Of Philadelphia$6,450,142
- Christopher A Miller · Washington University$5,424,298
- Eric Padron · H. Lee Moffitt Cancer Ctr & Res Inst$5,329,699
- Kelly Diringer Getz · University Of Pennsylvania$4,068,250
Research focus
Acute Myelocytic LeukemiaAcute LeukemiaAftercareAreaBasic ScienceAdultBiologicalCancer TypeCandidate Disease GeneCareerCell LineCellsChemoprotective AgentBiochemicalChemotherapyClinical CareClinical OncologyClinical SciencesCollaborationsCombined Modality TherapyComplementary DnaComplexDana-Farber Cancer InstituteDiagnosis
Grant awards (3)
Investigating the role of Strada signaling in promoting AML chemoresistance$51,036
F31 · FY2021 · CA · contact PI
Investigating the role of Strada signaling in promoting AML chemoresistance$50,520
F31 · FY2020 · CA · contact PI
Investigating the role of Strada signaling in promoting AML chemoresistance$49,524
F31 · FY2018 · CA · contact PI